Review Article
Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
Table 2
Ongoing clinical trials combining CDK4/6 inhibitors with HER2-targeted and antihormonal agents in patients with HR+/HER2+ breast cancer.
| Clinical trial | Therapeutic agents | Phase | Line of therapy Disease stage | Location |
| NCT03054363a | (i) Palbociclib (ii) Tucatinib (iii) Letrozole | Ib/II | line and beyond Stage IV | United States ABRCC consortium |
| NCT02947685 (PATINA) | (i) Palbociclib (ii) Trastuzumab (iii) Pertuzumab (iv) Any AIb or fulvestrant | III | line maintenance after cycles of induction chemotherapy Stage IV | United States Alliance foundation |
| NCT02907918 (PALTAN) | (i) Palbociclib (ii) Trastuzumab (iii) Letrozole | II | Neo-adjuvant therapy Stage II, III | United States |
| NCT02675231 (MonarcHER2) | (i) Abemaciclib (ii) Trastuzumab (iii) Fulvestrant | II | line and beyond Stage IV | Worldwide |
| NCT02448420 (PATRICIA) | (i) Palbociclib (ii) Trastuzumab (iii) Letrozole | II | to line of therapy Stage IV | Spain SOLTI group |
| NCT02530424 (NA-PHER2) | (i) Palbociclib (ii) Trastuzumab (iii) Pertuzumab (iv) Fulvestrant | II | Neo-adjuvant therapy Stage I-III | Italy |
| NCT03304080 | (i) Palbocilib (ii) Trastuzumab (iii) Pertuzumab (iv) Anastrozole | I/II | line Stage IV | United States |
|
|
a: clinical trial number in the US National Institutes of Health clinical trial database; b–AI: aromatase inhibitor.
|